1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Affimed NV (AFMD)
  7. Quote


Affimed NV Stock Price

-0.10 (-1.41%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,161,682
Bid Price 6.70
Ask Price 7.20
News -
Day High 7.13


52 Week Range


Day Low 6.78
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -1.41% 6.97 17:00:01
Open Price Low Price High Price Close Price Prev Close
6.97 6.78 7.13 6.97 7.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,570 1,161,682 $ 6.95 $ 8,068,405 - 4.78 - 11.74
Last Trade Time Type Quantity Stock Price Currency
16:07:31 6 $ 6.99 USD


Draw Mode:

Affimed NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 834.99M 119.80M 116.48M $ 34.39M $ -32.03M -0.61 -12.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Affimed NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AFMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.817.356.366.974,954,2230.162.35%
1 Month6.637.355.506.632,988,1580.345.13%
3 Months7.107.355.506.501,591,896-0.13-1.83%
6 Months8.779.22995.436.891,360,561-1.80-20.52%
1 Year5.2011.744.787.761,998,4281.7734.04%
3 Years4.6711.741.425.651,237,9482.3049.25%
5 Years2.3011.741.155.11996,4644.67203.04%

Affimed NV Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Your Recent History
Affimed NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.